Moreover, targeting survivin with siRNA or miRNA re-sensitizes drug-resistant breast cancer cell lines to chemotherapeutic agents, including paclitaxel, taxol, and Dox [33,34]. This evidence concerns the gene BIRC5 and breast carcinoma.